Download PDF
Thromb Haemost 1997; 78(03): 0990-0992
DOI: 10.1055/s-0038-1657674
Rapid Communication
Schattauer GmbH Stuttgart

The 20210 A Allele of the Prothrombin Gene Is a Common Risk Factor among Swedish Outpatients with Verified Deep Venous Thrombosis

Andreas Hillarp
1   The Departments of Clinical Chemistry, Lund University, University Hospital, Lund, Sweden
,
Bengt Zӧller
3   The Department of Internal Medicine, Lund University, University Hospital, Lund, Sweden
,
Peter J Svensson
2   The Coagulation Disorders, Lund University, University Hospital Malmö, Sweden
,
Bjӧrn Dahlbäck
1   The Departments of Clinical Chemistry, Lund University, University Hospital, Lund, Sweden
› Author Affiliations
Further Information

Publication History

Received 13 1997

Accepted after revision 12 May 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A dimorphism in the 3’-untranslated region of the prothrombin gene (G to A transition at position 20210) has recently been reported to be associated with increases in plasma prothrombin levels and in the risk of venous thrombosis (1). We have examined the prothrombin dimorphism among 99 unselected outpatients with phlebography verified deep venous thrombosis, and in 282 healthy controls. The prevalence of the 20210 A allele was 7.1% (7/99) in the patient group, and 1.8% (5/282) in the healthy control group (p = 0.0095). The relative risk of venous thrombosis was calculated to be 4.2 (95% Cl, 1.3 to 13.6), and was still significant when adjustment was made for age, sex and the factor V:R506Q mutation causing APC resistance [odds ratio 3.8 (95% Cl, 1.1 13.2)]. As previously reported, 28% of the patients were carriers of the factor V:R506Q mutation. Thus, 34% (one patient carried both traits) of unselected patients with deep venous thrombosis were carriers of an inherited prothrombotic disorder. To sum up, our results confirm the 20210 A allele of the prothrombin gene to be an important risk factor for venous thrombosis.

 

  • References

  • 1 Poort SW, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703
    PubMedGoogle Scholar
  • 2 Kierkegaard A. Incidence of acute deep vein thrombosis in two districts. A phlebographic study. Acta Chir Scand 1980; 146: 267-269
    PubMedGoogle Scholar
  • 3 Hirsch J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986; 08 Supp B 104B-113B
    CrossrefPubMedGoogle Scholar
  • 4 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-161
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Heijboer H, Brandjes D, Büller HR. et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
    CrossrefPubMedGoogle Scholar
  • 6 Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease – critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 07-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 8 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de RondeH, van der VeldenPA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
    CrossrefPubMedGoogle Scholar
  • 9 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-1363
    PubMedGoogle Scholar
  • 10 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
    CrossrefPubMedGoogle Scholar
  • 11 Zӧller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1996; 343: 1536-1538
    PubMedGoogle Scholar
  • 12 Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993
    PubMedGoogle Scholar
  • 13 Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
    CrossrefPubMedGoogle Scholar
  • 14 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521
    CrossrefPubMedGoogle Scholar
  • 15 Degen SJF, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry 1987; 26: 6165-6177
    CrossrefPubMedGoogle Scholar
  • 16 Royle NJ, Irwin DM, Koschinsky ML, MacGillivray RTA, Hamerton JL. Human genes encoding prothrombin and ceruloplasmin map to lip 11-q 12 and 3q21-24, respectively. Somat Cell Mol Genet 1987; 13: 285-292
    CrossrefPubMedGoogle Scholar
  • 17 Jackson CM. Physiology and biochemistry of prothrombin. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds. Churchill Livingstone; Edinburgh, UK: 1994. pp 397-438
    Google Scholar
  • 18 Bertina RM, van TilburgNH, de Fouw NJ, Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann NY Acad Sci 1992; 667: 239-248
    CrossrefPubMedGoogle Scholar
  • 19 Dang QD, Vindigni A, Di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 1995; 92: 5977-5981
    CrossrefPubMedGoogle Scholar
  • 20 Svensson PJ, Zöller B, Mattiasson I, Dahlbäck B. The factor V:R506Q mutation causing APC resistance is highly prevalent among unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 1997; 241: 379-386
    CrossrefPubMedGoogle Scholar
  • 21 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
    CrossrefPubMedGoogle Scholar
  • 22 Zӧller B, Holm J, Svensson PJ, Dahlbäck B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with inherited APCresistance and/or protein S deficiency. Thromb Haemost 1996; 75: 270-274
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Simioni P, Scarano L, Gavasso S, Sardella C, Girolami B, Scudeller A, Girolami A. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC-resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-441
    CrossrefPubMedGoogle Scholar
  • 24 Bauer KA. New markers for in vivo coagulation. Current opinion in Hematology 1994; 01: 341-346
    PubMedGoogle Scholar
  • 25 Mannucci PM. Mechanisms, markers and management of coagulation activation. Br Med Bull 1994; 50: 851-870
    CrossrefPubMedGoogle Scholar